Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2015 December;67(6) > Minerva Ginecologica 2015 December;67(6):533-44





A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Ginecologica 2015 December;67(6):533-44

language: English

Individualizing HT considering metabolic risk factors and breast cancer

Palacios S., Mejía Rios A.

Palacios’ Institute of Women’s Health, Madrid, Spain


Despite the time and evidence from observational studies, the balance between risk and benefit of using hormone therapy (HT) in postmenopausal women without comorbidities remains uncertain. HT for menopausal symptoms remains in use mainly to relieve vasomotor symptoms, but still leaves questions about its effect in preventing chronic diseases. The Women Health Initiative researched how to focus on defining and identifying the risks and benefits of HT with estrogen only and estrogen plus progestin on the risk of chronic diseases and other diseases such as coronary heart disease, breast and colorectal cancer and fractures in postmenopausal women, determining its safety and effectiveness. However, there is great concern about the increased risk found in breast cancer and cardiovascular disease using estrogen and progestin combined therapies versus estrogen only therapies, so an added risk to the use of progestin is awarded. For this reason there are new options to new treatment alternatives.

top of page

Publication History

Cite this article as

Corresponding author e-mail